SYNEDGEN, INC.

Synedgen, Inc. specializes in advanced research and development of novel medical countermeasures against acute radiation injury, with a focus on gut-restricted therapeutics and field-stable glycopolymer-mimicking polysaccharides. The company leverages expertise in pharmaceutical formulation, radiobiology, and polymer chemistry to develop orally administered, non-systemic agents that mitigate gastrointestinal injury from ionizing radiation exposure. Their technical capabilities include drug product optimization, preclinical candidate development, and translational science bridging laboratory findings to deployable medical solutions for high-risk operational environments. Synedgen’s key differentiator lies in its precision targeting of radiation-induced GI morbidity using proprietary molecular designs that preserve intestinal integrity without systemic absorption, enabling safe, rapid-response deployment in mass casualty scenarios. The company has delivered mission-critical R&D services to the Department of Health and Human Services and the Department of Defense, primarily supporting biomedical defense initiatives under SBIR and direct contract mechanisms. For HHS, Synedgen advances therapeutic candidates for radiological emergency preparedness; for DoD, it develops durable, stable countermeasures suitable for field use by military and first responder units. These engagements reflect a consistent alignment with federal bio-defense priorities and a proven ability to meet stringent operational requirements for medical readiness. Synedgen’s primary focus is in NAICS 541715, where it applies physical and life sciences research to develop medical countermeasures for acute environmental threats. The firm occupies a niche in radiation pharmacology, distinguishing itself through innovative polymer-based drug delivery systems and targeted GI protection strategies. This positions Synedgen as a specialized provider in the federal bio-defense and medical countermeasure innovation space. As a small business structured as a 2L entity based in Claremont, California, Synedgen operates with agility and scientific rigor. While currently holding no formal government certifications, its technical track record and mission-focused R&D approach establish strong credibility within federal science and defense communities.